General information
Immatics N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Baden-Württemberg
Germany
Contact person: Andrea Mayer-Mokler, Vice President Global Head of Clinical Sciences
Company main phone: +49 (7071) 53970
Company main fax: +49 (7071) 5397900
Website: https://www.immatics.com
Year founded: | 2000
|
Source of foundation: | Spin-off from university |
Name of foundation source: | H.G. Rammensee's laboratory at the University of Tübingen, Germany |
No. of employees: |
Worldwide: 646 |
Corporate description / mission:
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies. The company's clinical ACTengine® programs are based on genetically engineering a patient’s own, autologous T cells with novel TCRs designed to recognize the cancer target on the tumor. The engineered T cells (TCR-T) aim to induce a robust and specific anti-tumor attack to fight the cancer. The company's TCER® IMA401 is Immatics’ most advanced TCER® molecule from the Bispecifics pipeline that targets an HLA-A*02-presented (human leukocyte antigen) peptide derived from two different cancer-associated proteins, melanoma-associated antigen 4 and/or 8 (“MAGEA4/8”). The MAGEA4/8 peptide has been identified and validated by Immatics’ proprietary mass spectrometry-based target discovery platform XPRESIDENT® and is presented at a 5-fold higher copy number per tumor cell than the MAGEA4 peptide targeted in other clinical trials.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2020
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Antibodies
- Cell therapy
- Immunotherapy
- Peptides
|
Primary therapeutic areas: |
- Neoplasms / cancer / oncology
|
Business model: |
- In-licensing
- Out-licensing
- R&D
|
Customer segments: |
- Large biotech & big pharma
- Small biotech
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 7 | |
Phase I: | 2 | |
Phase II: | 2 | |
Description of products:
ACTengine® IMA203 (PRAME),
ACTallo® IMA30x,
TCER® IMA401 (MAGEA4/8), ect.
Special IP situation:
The XPRESIDENT technology is protected by granted patents and patent applications.
Technology used:
XPRESIDENT™
XCEPTOR®
Financing details
Fiscal year (end of) 2024
Revenues: | USD 163.14M | |
R&D expenses: | USD 155.02M | |
Net earnings: | USD 15.93M | |
Cash: | USD 247.85M | |
Total liabilities: | USD 126.99M | |
No. of shares: | 121'550'000 | |
Market cap. / valuation: | USD 743.89M | |
Collaborations & Clients
Partnering strategy / collaborations:
Editas
BMS
Moderna, etc.